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Introduction

As evidence mounts that antiretrovirals (ARVs)
are effective for HIV prevention, policymakers
and program managers will need to determine
whether and how best to introduce specific
products into health care systems. Determining
the most appropriate users within a particular
country will depend on the overall context, the
nature of the HIV epidemic within the country,
and the opportunities available to reach and serve
HIV-negative women with ARV-based prevention
products and services.

GUIDING PRINCIPLES
This toolkit was developed based on the belief that women
should have access to a wide range of options to prevent
HIV and have the ability to choose those that best meet
their needs. The following principles guided the creation of
this document:
• Equitable access to HIV prevention must take into
account the specific populations at risk. In many
countries, women and girls are at increased vulnerability
for HIV/AIDS given gender inequality, discrimination,
and stigma, and have few tools to mitigate their risk.

This toolkit was developed by the Population
Council for use by governments, organizations,
and donors that are in a position to support or
add new HIV-prevention products into programs.
The toolkit was designed to help identify strategic
opportunities for providing ARV-based products
to women. The most effective mix of program
entry points and delivery channels will vary from
country to country. Similarly, the particular role a
given product will play in a country will depend on
a range of epidemiological, health system, and
economic factors.

• Women-initiated technologies are needed, given
women’s widespread vulnerability to HIV infection
and the underlying social and normative factors that
contribute to their limited control over sexual relations.
• New HIV-prevention products for women should
complement existing prevention strategies and
products, including male and female condoms.
• The introduction of new products should be coordinated
and integrated with other services and programs to
capitalize on existing infrastructure and program efforts.
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About this Toolkit
Introducing Antiretroviral (ARV)-Based Prevention
Products for Women assists users in planning
for the introduction of new HIV-prevention products (and accompanying services) in a manner
that supports high-quality, integrated services.
It guides policymakers and program managers
through a systematic process of assessing the role
and potential impact of a new product into their
programs while considering the feasibility of
introducing it in specific settings.
This toolkit focuses on facility-based services;
provision of ARV-containing products will likely
be prescription-only at first and require capacity
for HIV testing and monitoring. It guides users
through a series of considerations to identify
potential barriers and assets within the service
setting, which should be considered in program
design and planning. This process will result in a
programmatic action plan for effective product
introduction in a manner that supports individuals’
rights and promotes quality services.
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NOTE: This document is not designed as a
detailed assessment tool. Numerous assessment
guides and programming tools have been developed to design HIV/AIDS programs and services
and to support integration of HIV/AIDS services
into existing programs. (See Appendix 1 for a list of
selected program and policy tools.) Most of these
tools are geared toward large-scale facility assessment and, therefore, require more time and resources to implement than the process proposed
here. Should it be required, these more in-depth
assessment tools can be used to follow up and
complement the action planning resulting from the
use of this toolkit.

HOW TO USE THIS TOOLKIT

Module 1: Landscape Analysis
Module 1
LANDSCAPE
ANALYSIS

Module 2
KEY OPINION 
LEADER AND
DECISIONMAKER 
DISCUSSION 
GUIDE

Module 3
PROGRAM
PLANNING
GUIDE

An analysis of the overall context of the HIV
epidemic, along with a policy and HIV program
scan, is an important first step. This analysis
consists primarily of a desk review of available
literature and data, supplemented as needed
with input from experts familiar with the HIV
epidemic and the specific country context. It
will serve as a starting point and foundation
for the process in Modules 2 and 3.

Module 2: Key Opinion
Leader and Decisionmaker
Discussion Guide

Module 3: Program
Planning Guide 
After gathering input from KOLs, a
facilitated workshop should be convened
that includes policymakers, service providers,
and program managers who are responsible
for implementing HIV-prevention programs.
Module 3 is designed to stimulate discussion
among these invited groups.

APPENDIXES
Appendix 1 contains key guidelines and
reference materials.

Another key component involves conducting
in-depth interviews (IDIs) with a select group
of key opinion leaders (KOLS) who will be
involved in or influence strategic decisions
about the introduction of new ARV-based
prevention products. Such KOLs can be identified from the “Potential Key Informants and
Organizations” box (see page 4). IDIs should
be conducted by a senior leader who is knowledgeable about both HIV prevention and the
country’s policy environment. Results will point
to the strategic role a given product could play
within a country’s HIV-prevention program and
help determine a plan for introduction.

Appendix 2 provides a detailed sample
workshop agenda.
Appendix 3 includes a checklist that will
assess the readiness of service-delivery
points for product delivery.
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GETTING STARTED
Completing this process will equip the team with the
elements needed to develop an introduction plan that
defines:

A small, in-country team will be needed to manage the
process. The team should include individuals with the
following attributes:
• An appropriate mix of skills and a professional
reputation to engage key decisionmakers and
program leaders, and to ensure follow-up;

• The strategic rationale for introducing a specific
new product;

• In-depth knowledge of the country’s health system and
its HIV-prevention program(s);

• Potential entry points and service settings for offering the product;

• Access to relevant professional networks;

• Steps and resources required to move forward at a
program level.

• Target populations to be served;

• Technical expertise with the specific product and any
associated service components.

Potential Key Informants and Organizations to Guide 
the INTRODUCTION Plan
• Policy decisionmakers and program planners
– Directors of HIV/AIDS, health, finance, and other related directorates
– Program directors from within health or other ministries
– Leaders of HIV/AIDS coordinating mechanisms
• Program managers, supervisors, and/or providers of clinical, primary, and
community health care (see list of settings, right)
• Managers of commodity security and logistics
• Key training institutions
• Nongovernmental, faith-based, private, and professional organizations,
particularly those focused on HIV-related services
• Advocates for women and for vulnerable and at-risk populations
• Social marketing groups   
• Development partners, including donors and technical-assistance agencies
4

Potential Service Settings 
for Delivering New ARV-Based 
Prevention Products
• Public-sector health centers
• HIV-counseling and testing sites
– Family planning/reproductive health/
    STI prevention and treatment services
• Maternal health settings, including
antenatal care
• Prevention programs for sero-positive and
sero-discordant couples
• Programs for vulnerable and most-at-risk
populations (MARPs)
• University-based health clinics and other
services designed to reach young people
(particularly girls and young women)

Module 1

LANDSCAPE
ANALYSIS

The desk review relies primarily on existing
datasets and publicly available information
from credible and referenced sources (for
example, Demographic and Health Surveys,
UNAIDS HIV country profiles, country-specific
plans and updates, if relevant). See Appendix
1 (Key Guidelines and Reference Materials)
for additional sources. The information should
be presented in brief narrative and tabular
form, with sources and citations provided.
The output should include a summary with
citations, data tables, appendixes of key
documents, and other reference materials, as
appropriate.

This module will facilitate the
creation of a landscape analysis
of the HIV epidemic in a particular
country.
The landscape analysis consists primarily
of a desk review, supplemented as needed
and as possible with expert opinion and
interviews with key informants. The analysis
and synthesis will provide an overview of
the nature and shape of the HIV epidemic in
the country as well as a general overview of
the policy environment and structure of the
country’s health system.
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  EPIDEMIOLOGICAL CONTEXT  

  POLICY ENVIRONMENT  

1 Describe the country’s HIV epidemic. Use:

4 Describe the country’s current HIV policies.

• National prevalence/incidence (stratified by age,
gender, state/province/district)
• Trends in prevalence/incidence (stratified by age
and gender)
• Populations with highest prevalence/incidence
• Coverage of antiretroviral therapy
• Important risk factors for women
• Age at first sex
• Age at marriage
• Concurrent sexual partnership patterns
• Intimate partner violence
• Most-at-risk populations (MARPs; defined
in country context)

• Which HIV-prevention approaches, including
technologies (e.g., reducing number of partners,
abstinence, oral pre-exposure prophylaxis [PrEP],
voluntary medical male circumcision [VMMC]) are
included in relevant policies? Which approaches are
emphasized in which policies and for which user
groups?
• Describe service guidelines and protocols (and
include in an accompanying Appendix, if available)
specifically geared toward:
–– HIV-prevention programs
–– HIV-treatment programs
–– HIV and family planning/reproductive health
integration

2 Describe results of Modes of Transmission

Studies (MTS), if available.

5 Is there documentation of any experiences

regarding technology introduction in the country
that can help inform the introduction of ARVbased prevention for women?

3 Describe current contraceptive use patterns.

• Contraceptive prevalence (by age and region)

• regarding male or female condoms, reproductive
health products, or antiretroviral therapy [ART],
for example

• Method mix; most commonly used method(s)
(by age and region)

If yes, summarize key lessons from these
experiences.

6

6 Which policies, regulatory authorities, and

10 What is the breakdown of funding for HIV-treatment

agencies are involved in the approval and
introduction of new HIV or reproductive health
products?

and prevention programs in the country?
• Note the approximate proportion of funding for
HIV treatment and prevention that comes from
different sources (e.g., national, provincial
government, donor organizations, private sector,
faith-based organizations, communication
resources, individual/family out-of-pocket).

7 Describe current policies, laws, and service-

delivery guidelines regarding the initiation,
dispensing, and resupply of ARV-containing
products.

• Note the roles that public/private partnerships and/
or social marketing play.
• Note the proportion of HIV expenditures by
commodities and programming for treatment and
for prevention, if available.

8 List any restrictions on HIV or SRH services.

Are they based on:
11 Provide recent statistics (national, provincial,

• Age
• Marital status

district) on use of these services, if available.

• Laws affecting key groups (sex workers,
injecting drug users, men who have sex with
men, etc.)

• HIV-treatment services
• HIV-prevention services (medical male circumcision, prevention of mother-to-child transmission,
postnatal care, post-exposure prophylaxis)
• Antenatal care

9 List any antidiscrimination laws protecting

• HIV counseling and testing

people living with HIV.

• Family planning
• Adolescent-related services
• STIs
• Other relevant services
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12 Which sector—public, nongovernmental

organization (NGO), or private—generally
takes the lead on new health innovations and
approaches?

  STRATEGIC OPPORTUNITIES  
13 Based on the available information and analysis,

what are the main strategic opportunities for
introducing ARV-based prevention for women?
What are the main challenges?

14 Are there any national initiatives that are ongoing

or to be launched that may have a bearing on the
introduction and financing of new products (e.g.,
National Health Insurance schemes, voucher
systems, re-engineering of primary health care)?

15 List other key insights or suggestions for

research, policy, or programming to initiate ARVbased prevention for women.
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Module 2

KEY OPINION 
LEADER AND
DECISIONMAKER 
DISCUSSION 
GUIDE

This module is designed to engage
key decisionmakers who will be
involved in or influence strategic
decisions regarding the introduction of antiretroviral (ARV)-based
prevention products for women.
By exploring views and eliciting expert
opinions, this module identifies key questions
and issues that must be considered and addressed to inform decisions about introducing new products in the context of a country’s
specific HIV epidemic, health system, and
political and economic environment.
Module 2 is structured as a questionnaire
intended to guide individual in-depth
interviews (IDIs) with carefully selected

key opinion leaders and decisionmakers.
The IDIs are conducted by a senior leader
working in the HIV field. As such, it assumes
a fairly high level of knowledge and awareness of critical issues in HIV prevention
and of the policymaking environment in
the country. The guide considers scientific,
political, and economic factors that drive
decisionmaking and general issues related
to health-system capacity.

This tool is flexible and can be adapted
for use in discussing a wide range
of ARV-based prevention products
for women, such as the dapivirine
intravaginal ring (IVR), Truvada for oral
pre-exposure prophylaxis (PrEP), and
other emerging technologies.
9

SCIENTIFIC EVIDENCE

TARGET POPULATIONS  

1 What scientific evidence would be needed

The introduction of a new HIV-prevention product can increase options for individuals to reduce their risk of infection
and holds the potential for a broader public health impact.

to make a decision to introduce
[insert specific product] in the country?
[Probe, as needed:]

3 In your view, who will benefit most from using

? Why? In which situations?
[Probe, as needed:]
[insert specific product]

• Safety data
–– In the general population

• Sero-discordant couples

–– In pregnant women

• Young women

–– During breastfeeding
–– In adolescents

• Married women (Married women whose husbands
work away from home)

–– Impact on current and future fertility

• Sex workers

• Effectiveness/level of efficacy (how well it works)
• Acceptability (and adherence)

• Women who have infrequent but risky sex (e.g.,
exchange sex for money, food, shelter)

• Potential resistance

• Women who have multiple partners
• Women whose partners have multiple partners

2 How should the data be made available to
4 Where do you see

[insert specific product] fitting into
the country’s HIV-prevention program vis-à-vis
existing strategies?

decisionmakers (e.g., results of randomized
controlled trials, journal articles, briefings)?
What source of data would support the
decisionmaking process?

(e.g., HIV counseling and testing, voluntary medical
male circumcision (VMMC), oral PrEP, condom
promotion, behavior-change communications)?

5 How would you prioritize

[insert specific product]

relative to other HIV-prevention strategies
and why?
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IMPACT ON HEALTH SYSTEMS

8 Are there lessons (positive and negative)

from the introduction of other technologies
or prevention strategies that could inform plans
for introducing [insert specific product] ?

6 What are the potential opportunities for

delivering [insert specific product] ? Through which
sectors and in which programs or services could
this occur? [Probe, as needed:]

POLICY CONSIDERATIONS

• Public vs. NGO vs. private sector
• Type of service

9 What do you see as the potential benefits and

–– Primary

risks from introducing
[Probe, as needed:]

–– Secondary
–– Tertiary

[insert specific product]

?

• Expanded options for prevention

• Type of program
–– ARV treatment

• Equity

–– HIV testing and counseling

• Reactions from various constituencies—religious,
community, advocacy groups

–– Voluntary medical male circumcision
–– Sexual and reproductive health
–– Antenatal care

10 Who are the key players (organizations) that

–– Family planning

must be engaged in the decision about whether
to introduce [insert specific product] ?
[Probe, as needed:]

–– Well-baby
–– Other

• Regulatory bodies (local and international)
7 If

• Guidelines from normative agencies (WHO, etc.)

was introduced in
the country, what would be the implications
for existing programs, services, and health
systems? [Probe, as needed:]
[insert specific product]

• Others

11 Are there champions for ARV-based prevention

• HIV-testing programs

or HIV prevention for women in the country who
could help advocate for [insert specific product] ?

• HIV-treatment programs
• SRH programs/services
• Staff deployment, task-shifting
11

ECONOMICS, COST, AND FINANCING

DECISIONMAKING  

Cost considerations, including manufacturing, often factor
heavily in decisions about whether, how, and at what scale new
health products should be produced and introduced. Many of
these are influenced nationally and globally.

17 If you were asked to make a decision today about

whether to introduce
would you do? Why?

[insert specific product]

, what

12 How would the decision be made whether to invest

in introducing

[insert specific product]

18 From your position and the role that you/your

?

agency plays, what other information/data would
you need to make a decision about introducing
[insert specific product] ?

13 What would you or other decisionmakers need to

know to make the investment case for [insert specific
product] in order to allocate a budget for product
procurement and introduction?

19 Is there anything else you would like to add?

14 How do you think this product could be financed in

the short term? The long term?

15 How could supplying

[insert specific product] to those
who need it be sustained over the long term?

16 From your experience, can you comment on key

issues to consider related to the following:
• Product-procurement mechanism
• Supply chain
• Manufacturing
• Pharmaco-vigillance/surveillance
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Module

3

PROGRAM
PLANNING
GUIDE

This module is designed to stimulate discussion among selected
service providers, policymakers,
and program managers who are
responsible for implementing
HIV-prevention programs.

  POLICY ENVIRONMENT  
1 How are new HIV-prevention methods

incorporated into national HIV policies and
strategic plans?

2 How are priorities set for HIV prevention and

The module provides key questions that
can be addressed through facilitated group
discussions in a workshop format (a sample
agenda is provided in Appendix 2). This
module leads participants through a series
of service-design considerations that need
to be addressed in program planning. The
outcome of this process is a plan for product
introduction that supports quality services
and clients’ rights.

treatment programs, and at what level of the
health system (national, provincial, or district)?

3 Which HIV-prevention approaches are

emphasized in current plans? Are different
approaches emphasized for different user
groups?
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TARGET POPULATIONS  

8 Which channels do these campaigns use?

Which do you think are most effective?
4 In your view, what populations would benefit

• Mass media

most from this product? [Probe, as needed:]

• Peer education

• Sero-discordant couples
• Young women

• Clinic-based information, education,
communication

• Married women

• Community education

• Sex workers

• Mobile and digital media

• Women who have infrequent but risky sex (e.g.,
exchange sex for money, food, shelter)
9 Do you have ideas about how best to create

• Women who have multiple partners

demand for this new product?

• Women whose partners have multiple partners

5 For each group that would benefit, where and

10 What specific lessons can be applied from other

how would they best be reached?

technology-introduction efforts?

 MESSAGING AND DEMAND CREATION  

11 What do you anticipate will be the key barriers

for women who wish to use the product?

6 Which organization is charged with developing

and/or maintaining messages for HIV prevention
generally? For ARV-based prevention for women
in particular?

12 How can existing programs be capitalized upon

to support introduction?

7 Describe key campaigns that are focused

on HIV prevention for women. How were
they developed? How would new ARV-based
prevention products or services for women be
best incorporated into these campaigns?
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SERVICE PROVISION 

15 In the settings that have been identified as

favorable for integrating ARV-based prevention for
women, are facilities generally adequate?

13 How well do you think HIV prevention is currently

integrated with these other health programs and
services?

Consider whether:
• Essential supplies/commodities (including HIV tests)
are routinely available

• Reproductive health
• Child health

• Facilities have patient-education materials on ARVbased prevention to support community- and clinicbased education

• Primary health

• Facilities are able to handle specific commodity
requirements (storage space, shelf life, temperature,
stock control, security, expiration)

14 ARV-based prevention products will require

counseling, HIV testing, and monitoring. Which
service settings might afford good opportunities for
delivering this product? [Probe, as needed:]

16 Is staffing generally adequate?

• HIV counseling and testing (HCT)?

• Given resource constraints, how might services be
provided and by whom?

• Family planning?
• School-based programs (adolescents)?

• Can you envision assigning clinic staff to the specific
task of providing clients with, and counseling them on,
this product?

• Antenatal care?
• Services for sero-discordant couples?

• Would there be opportunities for training different
cadres of staff in ARV-based prevention and
counseling?

• Sexually transmitted infection services?
• Primary health?

17 How do existing human resource training strategies

incorporate:
• HIV-prevention approaches?
• Family planning/reproductive health?
• HIV treatment, counseling, and care?
• Are there specific training materials or curriculums
that could be adapted to include ARV-based
prevention for women?
15

18 What staffing will be needed to support the

21 What commodities are currently available for HIV

introduction of a new ARV-based prevention
product for women?

prevention (e.g., HIV test kits, male condoms,
female condoms)? And:

• Which cadres of health personnel (e.g., nurses,
physicians, counselors, health officers)?

• Who provides them?
• Who pays for them (e.g., national government, donor
agencies)?

• At which levels of the health system (district,
province, community)?

• What client fees or cost-sharing is levied on these
commodities?
• How would a new product be added to the HIV
commodities-procurement list?

19 What do you foresee as the key challenges

providers may face in offering ARV-based
prevention products for women?

• What do you think will be the challenges regarding
procurement and supply of ARV-based products?

 COMMODITIES/SUPPLY CHAIN/LOGISTICS

IMPLICATIONS/SPECIAL CHALLENGES

20 Is there an effective commodity-security

22 Do you have any concerns related to an ARV-based

prevention product that uses the same active drug
used in treatment regimens?

program (for HIV and/or reproductive health
commodities) that currently exists and could
be used for new HIV-prevention products? If
not, what areas of the supply chain require
strengthening?

• Real or perceived tension between resources for
treatment and prevention?
• Potential resistance?

23 Are there systems for post-marketing surveillance

and pharmaco-vigilance that can be used to track
HIV resistance, adverse events, or side effects
related to ARV-based prevention products?

16

Appendixes

Appendix 1
Key Guidelines and Reference Materials
The key guidelines found in the toolkits and manuals listed below have been produced by collaborating agencies and other major institutions known
for their work within the fields of HIV/AIDS and sexual/reproductive health.
Bristol-Myers Squibb Foundation, Southern
Africa HIV Clinicians Society and International
Training and Education Center on HIV (I-TECH).
2007. “Secure the future manual: Seven steps
to involve the community in HIV/AIDS treatment support programmes, first edition.”
New York: Bristol-Myers Squibb Foundation.
http://www.securethefuture.com/our_
experience/STF_manual_first_edition.pdf
Farrell, Betty L. 2007. “Family planning–
integrated HIV services: A framework for
integrating family planning and antiretroviral
therapy services.” New York: EngenderHealth/
ACQUIRE Project. http://www.acquireproject.
org/fileadmin/user_upload/ACQUIRE/
Publications/FP-HIV-Integration_framework_
final.pdf
FHI360. 2008. “Increasing access to contraception for clients with HIV: A toolkit.” Research
Triangle Park, NC: FHI360. http://www.fhi360.
org/training/en/modules/FPHIV_toolkit/
interface.pdf
Futures Group. 2000. “The AIDS impact model
(AIM) approach.” Washington, DC: Futures
Group/POLICY Project. http://www.
policyproject.com/pubs/bookgreen.pdf

International AIDS Vaccine Initiative (IAVI). 2009.
“Integrating gender issues into AIDS vaccine
clinical research: A training manual for SubSaharan Africa.” New York. http://www.iavi.org/
Lists/IAVIPublications/attachments/
c92467a3-8da3-4c83-8ba2-2520acf93518/
IAVI_Integrating_Gender_Issues_into_AIDS_
Vaccine_Clinical_Research_2009_eng.pdf
International HIV/AIDS Alliance. 2010. “Integration of HIV and sexual and reproductive health
and rights: Good practice guide.” Brighton, UK.
http://www.aidsalliance.org/includes/
Publication/SRHGPG2.pdf
John Snow, Inc. (JSI). 2009. “Quantification of
health commodities: A guide to forecasting
and supply planning for procurement.” Arlington, VA: JSI–USAID DELIVER Project, Task
Order 1. http://sc4ccm.jsi.com/Docs/
QuantHealthCommunity.pdf
Joint United Nations Programme on HIV/AIDS
(UNAIDS). 2011. “Joint strategic action framework to accelerate the scale-up of voluntary
medical male circumcision for HIV prevention
in Eastern and Southern Africa.” Geneva:
UNAIDS. http://www.unaids.org/en/media/
unaids/contentassets/documents/unaids
publication/2011/JC2251_Action_Framework_
circumcision_en.pdf
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K4Health. 2014. “Microbicides toolkit.” Research
Triangle Park, NC: FHI360. http://www.
k4health.org/toolkits/microbicides
MacQueen, Kathleen and Mike May. 2008.
“Partnering for care in HIV prevention trials:
A how-to manual.” Research Triangle Park, NC:
FHI360. http://www.fhi360.org/resource/
partnering-care-hiv-prevention-trialshow-manual
Patel, A. et al. 2010. “Pediatric HIV treatment
toolkit: A practical guide to the implementation
of the 2009 World Health Organization pediatric HIV treatment recommendations.” Arlington, VA: USAID AIDSTAR-One Project, Task
Order 1. http://www.aidstar-one.com/sites/
default/files/AIDSTAR-One_HIV_Pediatric_
Treatment_Toolkit.PDF
Raney, Laura et al. 2008. “Balanced counseling
strategy plus user’s guide,” in The Balanced
Counseling Strategy Plus: A Toolkit for Family
Planning Service Providers Working in High
STI/HIV Prevalence Settings. Washington, DC:
Population Council. http://www.popcouncil.
org/pdfs/frontiers/Manuals/BCSPlus/BCSPlus_UsersGuide.pdf

Robinson, Elizabeth T. et al. 2010. “Communications handbook for clinical trials: Strategies,
tips, and tools to manage controversy, convey
your message, and disseminate results.”
Research Triangle Park, NC: FHI360/
Contraceptive and Reproductive Health
Technologies Research and Utilization
Program. http://www.fhi360.org/resource/
communications-handbook-clinicaltrials-strategies-tips-and-tools-managecontroversy-convey
Ross, John and Ellen Smith. 2010. “The family
planning effort index: 1999, 2004, and
2009.” Washington, DC: Futures Group/
Health Policy Initiative. http://www.
healthpolicyinitiative.com/Publications/
Documents/1110_1_FP_Effort_Index_1999_
2004_2009__FINAL_05_08_10_acc.pdf
Sanders, Rachel, Karen Hardee, and Carol
Shepherd. 2007. “Implementing integrated
family planning and HIV/AIDS policies and
programs: Tools and resources.” Washing-

ton, DC: Futures Group/POLICY Project.
http://www.policyproject.com/pubs/
generalreport/ImplementingPoliciesand
Programs.pdf
USAID, Center for Accelerating Innovation and
Impact (CII). 2015. “Idea to impact. A guide
to introduction and scale of global health
innovations.” Washington, DC: CII. http://
www.usaid.gov/cii/guide-introductionand-scale
World Health Organization (WHO). 2004.
“A guide to rapid assessment of human
resources for health.” Geneva: WHO.
http://www.who.int/hrh/tools/en/
Rapid_Assessment_guide.pdf
———. 2009. “Integrating gender into HIV/
AIDS programmes in the health sector:
Tool to improve responsiveness to women’s
needs.” Geneva: WHO. http://www.who.int/
gender/documents/gender_hiv_
guidelines_en.pdf
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WHO, International HIV/AIDS Alliance, and
PharmAccess International. 2003. “A public
health approach for scaling up antiretroviral
treatment: A toolkit for programme managers.” Geneva: WHO. http://www.who.int/hiv/
pub/prev_care/arvtoolkit_en.pdf
WHO, United Nations Population Fund,
UNAIDS, and International Planned Parenthood Foundation. 2005. “Linking sexual
and reproductive health and HIV/AIDS: An
annotated inventory.” Geneva: WHO. http://
www.who.int/hiv/pub/prev_care/inventoryfinal.pdf

Listed in the table below are program and policy tools that were reviewed prior to and informed the development of this toolkit.
Instrument Name

Developer

Date

Description

Where Used/Tested

Assessing Integration Methodology
(AIM)

FRONTIERS—
Population Council

2008

Can be used by decisionmakers to assess the feasibility of linking services, identify programmatic
or structural barriers to integration, pilot-test approaches to integrating services, evaluate effects
of linked or integrated services, and assess/evaluate costs of integrated services models.

Multiple country settings,
including Bangladesh,
Bolivia, Dominican
Republic, Egypt, Ghana,
Guatemala, India, Kenya,
Nicaragua, South Africa,
and Uganda.

EngenderHealth

2008

Field-tested in Uganda.
Provides materials for identifying and solving onsite problems that compromise the quality of HIV Used in multiple country
settings.
care and treatment services. The tools address:
informed consent, confidentiality, clinical management of HIV, provision of ART, positive prevention,
and integration of SRH and HIV services.

Health Policy
Initiative—
Futures/UNAIDS

2009

This tool was developed to enable decisionmakers Botswana, Lesotho,
Namibia, Swaziland,
to understand the potential cost and impact of
Uganda, and Zambia.
various options for scaling up male circumcision
services within their particular country setting.

INFO Project—
JHU/CCP and
WHO

2005/
2006

Designed for use by family planning providers
to help clients make informed choices about
contraceptive methods and to give clients the
information and help they need to use their chosen method successfully. Adaptation guidelines
provided for specific methods and contexts.

Indonesia, Mexico,
Nicaragua, South Africa,
and Trinidad and Tobago.

Measure DHS

Multiple
years

Offers a comprehensive overview of a country’s
health-care services and its capacity to provide
quality care. SPA surveys examine the supply side
of health care, showing the strengths and weaknesses of a country’s public and private services.
It focuses on five key services: child health, maternity and newborn care, family planning, STIs and
other infectious diseases, and HIV/AIDS.

Multiple countries.

www.popcouncil.org/pdfs/frontiers/
Manuals/AIM.pdf

COPE® for HIV Care and Treatment
Services: A Toolbook to Accompany the
COPE® Handbook
www.engenderhealth.org/files/pubs/qi/
cope_hiv_care_treatment.pdf
Decision Makers’ Program Planning Tool
(DMPPT): Calculating the Costs and Impacts of a Male Circumcision Program
http://www.malecircumcision.org/
resource/decision-makers%E2%80%99program-planning-tool-dmppt-manual
Decision-making Tool for Family
Planning Clients and Providers +
Technical Adaptation Guide
whqlibdoc.who.int/publications/
2005/9241593229_eng.pdf
www.who.int/reproductivehealth/
publications/family_planning/Technical_
adaptation_guide.pdf
Demographic and Health Surveys Service Provision Assessments (DHS SPA)
www.dhsprogram.com/What-We-Do/
Survey-Types/SPA.cfm

(continued)
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Instrument Name

Developer

Date

Description

Where Used/Tested

Facility Audit of Service Quality (FASQ)

Measure
Evaluation

2008

Provides information on types of service, status
and functionality of infrastructure, equipment,
and quality of care. It facilitates local (e.g., project- or district-level) and low-cost monitoring of
availability and quality of facility-based reproductive and child-health services at government and
private facilities, including private clinics.

Bangladesh, Bolivia, Kenya,
and Tanzania.

FHI360

2007

Tool is designed to help governments and
organizations determine availability/quality
of essential elements of HIV services, gather
necessary data about these services, and plan for
program implementation.

Cambodia, Ethiopia, Kenya,
Nigeria, Rwanda, Senegal,
and Zambia.

Health
System 20/20—
Abt Associates

2010

Developed to assist governments and donors with
the development of HIV/AIDS policies and implementation plans.

Cote d’Ivoire, Guyana,
Haiti, Kenya, Nigeria, Sierra
Leone, South Sudan, and
Zambia.

2004

A review was conducted of instruments that were
used in this study to explore and identify issues
that could facilitate or undermine access to and
use of microbicides.

South Africa.

(Report only. Tools available upon request.)

EngenderHealth,
International
Partnership for
Microbicides, UCT
Women’s Health
Research Unit,
Population Council

What Is the Policy Environment Score
(PES)?

Policy Project—
Futures

1997

Jamaica, Jordan, Nigeria,
Designed to measure the overall status of the
and Uganda.
policy environment for SRH, FP, adolescent RH,
HIV/AIDS, safe motherhood, and PAC in a particular
country, evaluating changes in the policy environment over time and identifying those areas most
in need of improvement.

Pathfinder

2003

Enables those involved in health management
to collect detailed information on the range and
quality of integrated services available at a given
facility and thus to facilitate the design of more
effective program interventions.

ihfan.org/home/index.php?editable=
no&page_type=catalog

Health Facility Tool to Assess
Preparedness for HIV Service Delivery,
including Antiretroviral Therapy
www.aidsdatahub.org/sites/default/files/
documents/Health_Facility_Tools_to_Assess_
Preparedness_for_HIV_Services_Delivery_
Including_Antiretroviral_Therapy.pdf.pdf
HIV/AIDS Program Sustainability Analysis
Tool (HAPSAT): MoH Questionnaires
pdf.usaid.gov/pdf_docs/PNADX754.pdf
Paving the Path: Preparing for
Microbicide Introduction
www.engenderhealth.org/files/pubs/
hiv-aids-stis/paving_the_path.pdf

www.policyproject.com/policycircle/
content.cfm?a0=3f
QOC for Integrated Services –
Clinic Assessment Guide
www.pathfind.org/site/DocServer/QOC_
document_oct_6.pdf?docID=1581

21

Nigeria.
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Instrument Name

Developer

Date

Description

Where Used/Tested

Rapid Assessment Tool for Sexual and
Reproductive Health and HIV Linkages

IPFP, UNFP, WHO,
UNAIDS, et al.

2009

Can be used to assess links between HIV and SRH
at policy, program, and facility levels, and ultimately contribute to the development of countryspecific action plans to forge and strengthen
linkages.

19 countries in Africa, Asia,
Central America, and the
Russian Federation.

EngenderHealth

2011

Designed to help determine strengths and
weaknesses in FP programs by identifying gaps
that require further investment or more in-depth
assessment prior to (re)designing interventions.

Burkina Faso, Mali, Nigeria,
Rwanda, Senegal, and
Togo.

John Snow, Inc.
(JSI)

2007

This tool was designed to provide sites and programs with a set of criteria to assess a site’s readiness to implement ART or the current capacity
and needs of an existing program, and to identify
key areas that need strengthening.

Field tested in Zimbabwe.
Used in multiple country
settings.

whqlibdoc.who.int/hq/2009/91825_eng.pdf
SEEDTM Assessment Guide for Family
Planning Programming
www.engenderhealth.org/seed
Tool to Assess Site Readiness for Initiating
Antiretroviral Therapy (ART) or Capacity
for Existing ART Sites, Version 1.3
deliver.jsi.com/dlvr_content/resources/
allpubs/guidelines/ToolAsseSiteRead.pdf
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Appendix 2
Sample Agenda
This sample details a facilitated discussion on program planning for tenofovir gel introduction. The agenda is based on Module 3: Program Planning
Guide and outlines how a 1- or 1½-day workshop could be convened with country stakeholders to explore program implementation issues. Specific
approaches to facilitation and the time allotted for each section will depend on the context, the size of the group, and attendees’ backgrounds.
PROGRAM PLANNING FOR TENOFOVIR GEL INTRODUCTION
Session 1
(0.5 hour)

Introduction
Welcome, participant introduction, purpose of meeting

Session 2
(1.5 hours)

Purpose: Ensure that all participants share a common understanding
about tenofovir gel as well as technical and contextual factors related
to its introduction.

Session 4
(1.5 hours)

Small-group discussion: What opportunities and challenges
should be addressed in a program plan for tenofovir gel
introduction?
• Break into four groups, ensuring that each includes at least
two participants with expertise in the discipline related to the
specific program component being discussed:
–– Policy environment
–– User perspectives and demand creation
–– Service provision
–– Commodities, supply chain, and logistics
• Ask participants to review selected questions from Module 3
related to these topics
• Report back in plenary; facilitator to synthesize key issues to
address in introduction and implementation.

Setting the stage (plenary presentations by technical experts):
• Technical update on tenofovir gel (expert slides will be provided,
detailing mechanism of action, status of clinical trials and
research, and key issues for service delivery)
• Summary of results of landscape analysis (Module 1)
• Summary of results from interviews with key opinion leaders and
decisionmakers (Module 2)
				–break–
Session 3
(1.5 hours)

Purpose: Participants examine specific program components
to identify issues that must be included in a program plan.

Purpose: Participants consider the information from the previous
session to identify strategic roles that tenofovir gel could play.

–break–

Small-group discussion: What role could tenofovir gel play in the
country?
• Break participants into small groups mixed by discipline
(policymakers, managers, providers)
• Ask groups to consider key questions from Module 3, such as:
–– Based on the HIV epidemic in the country, who do you think
will most benefit from tenofovir gel?
–– Based on the country’s health-system capacity, which
service settings afford good opportunities for implementing
tenofovir gel?
–– What do you think will be the key barriers/obstacles for women
who wish to access tenofovir gel?
–– What key challenges might providers face in providing
tenofovir gel?
• Report back in plenary; facilitator synthesizes input to develop a goal
statement that can guide tenofovir gel introduction.

Session 5
(1 hour)

Purpose: Discuss special issues and challenges related to
tenofovir gel.
Expert panel discussion: What are some key implications and
special challenges for introducing tenofovir gel?
• A panel of in-country and international experts highlight
selected issues from Module 3 about the impact tenofovir gel
could have on HIV testing, potential resistance, and prevention
options/method mix for HIV prevention, followed by a
facilitated discussion and brainstorming with all participants
to identify implications and issues.

Session 6
(0.5 hour)

Purpose: Summarize key points from the discussions, identify
and prioritize next steps.
Conclusions and next steps: The way forward
–adjourn–

–break–
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Appendix 3
A Checklist for Service-Delivery Readiness
This checklist is intended for use by program managers and health providers
to determine the readiness of service-delivery points to deliver ARV-based prevention for women. The checklist is administered through direct observation
by trained observers and/or researchers and can be used to: 1) identify key
areas requiring attention prior to initiating ARV-based prevention services; or
2) support the monitoring of related services once a product is introduced. The
checklist promotes high-quality services and interactions between client and
provider and is divided into two sections:

• SECTION I reviews overarching operations and facility-level components
necessary for safe and effective product delivery.
• SECTION II reviews staffing/human resource and provider components essential to deliver the product and to support provider–client interaction that
ensures informed choice and decisionmaking concerning product adoption.
The checklist should be updated and revised once service-delivery guidelines
and protocols for a specific product are developed.

SECTION I:  
OPERATIONS, GUIDELINES, FACILITY-RELATED ELEMENTS
1. Written medical guidelines, protocols, and standards for ARV-based
prevention exist and are available at the site.
2. Facilities have the necessary equipment and supplies to provide the
product, including (to be modified depending on specific product):
· HIV test kits
· Pelvic models (at training facilities)
· Other
3. A range of HIV-prevention options are available and in stock
at the site.
4. The facility has adequate space to ensure confidential HIV testing
and counseling.
5. The facility has adequate space and conditions (temperature and
humidity control, security, etc.) to store the product.
6. The facility has a system to forecast supply (and resupply)
requirements, and uses it to prevent stock-outs.
7. Client records are maintained and kept confidential.
8. The facility has guidelines and clear linkages to facilitate integrated
services and referrals as needed.
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Yes

No

Comments

__________________________
__________________________
__________________________
__________________________
__________________________
__________________________
__________________________
__________________________
__________________________
__________________________
__________________________
__________________________
__________________________
__________________________
__________________________
__________________________
__________________________

SECTION II:  
PROVIDER COMPETENCY, TRAINING, AND CLIENT
INTERACTION

Yes

1. Providers have been trained to provide ARV-based
prevention for women.
2. Providers have job aids that include clear, up-to-date
information about the product.
3. Providers follow protocols for infection prevention and safe
disposal of medical waste.
4. A system is in place to periodically assess staff competency
and training needs.
5. Providers counsel clients about HIV testing and retesting,
and on all available HIV-prevention options.
6. Providers ask clients about their reproductive intentions and, if
desired, counsel and provide contraception or refer clients.
7. Providers ensure client privacy and confidentiality.
8. Providers ensure that clients understand how the product
works, including risks/benefits, side effects, effectiveness.
9. Providers give instructions to clients about how to use, care
for, store, and dispose of product and related supplies.
10. Providers are respectful of clients and tailor their interaction
to clients’ needs, circumstances, and concerns.
11. Providers use language that clients understand and check to
ensure comprehension.
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No

Comments

__________________________
__________________________
__________________________
__________________________
__________________________
__________________________
__________________________
__________________________
__________________________
__________________________
__________________________
__________________________
__________________________
__________________________
__________________________
__________________________
__________________________
__________________________
__________________________
__________________________
__________________________
__________________________

		

Notes
_______________________________________________________________________________________________
_______________________________________________________________________________________________
_______________________________________________________________________________________________
_______________________________________________________________________________________________
_______________________________________________________________________________________________
_______________________________________________________________________________________________
_______________________________________________________________________________________________
_______________________________________________________________________________________________
_______________________________________________________________________________________________
_______________________________________________________________________________________________
_______________________________________________________________________________________________
_______________________________________________________________________________________________
_______________________________________________________________________________________________
_______________________________________________________________________________________________
_______________________________________________________________________________________________
_______________________________________________________________________________________________
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Notes
_______________________________________________________________________________________________
_______________________________________________________________________________________________
_______________________________________________________________________________________________
_______________________________________________________________________________________________
_______________________________________________________________________________________________
_______________________________________________________________________________________________
_______________________________________________________________________________________________
_______________________________________________________________________________________________
_______________________________________________________________________________________________
_______________________________________________________________________________________________
_______________________________________________________________________________________________
_______________________________________________________________________________________________
_______________________________________________________________________________________________
_______________________________________________________________________________________________
_______________________________________________________________________________________________
_______________________________________________________________________________________________
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